Harmonic Discovery
Harmonic Discovery designs single drugs that hit several disease-driving proteins at once, arguing that cancer is rarely caused by one broken protein.
Overview
Harmonic Discovery is a computational-experimental drug discovery company designing multi-targeted small molecules, principally kinase inhibitors, whose target profiles are chosen to hit several dysregulated proteins in a cancer at once while avoiding those that cause toxicity. The company argues that rational polypharmacology can be more effective and safer than one-drug-one-target agents. Programmes are preclinical; no sourced financing rounds are recorded here.
Funding
All startupsPages like this
not linked directly; found by shared links- CompanyReverie Labs
Shares Y Combinator, AI-driven drug & target discovery, Small-molecule kinase inhibitors and the tag yc.
- CompanyResistanceBio (Viosera Therapeutics)
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanySerinus Biosciences
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyAlixia
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.
- CompanyBlank Bio
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyAlgen Biotechnologies
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyAltay Therapeutics
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.